Xin Lang Cai Jing·2025-08-28 07:22Group 1 - The core point of the news is that Kelun Pharmaceutical's stock has experienced a decline, with a 6.65% drop over the last three days, closing at 36.49 yuan per share on August 28, with a total market capitalization of 58.313 billion yuan [1][2] - Kelun Pharmaceutical, established on May 29, 2002, and listed on June 3, 2010, is primarily engaged in the development, production, and sales of large-volume infusion products, with revenue composition as follows: non-infusion products 47.22%, infusion products 40.86%, R&D projects 8.69%, and others 3.24% [1] - The fund "Guotai Haitong Asset Management" holds a significant position in Kelun Pharmaceutical, with the Guotai Junan Innovative Medicine Mixed Fund A (014157) reducing its holdings by 20,000 shares in the second quarter, now holding 212,200 shares, which represents 5.06% of the fund's net value [2] Group 2 - The Guotai Junan Innovative Medicine Mixed Fund A has reported a year-to-date return of 21.75% and a one-year return of 30.62%, ranking 3157 out of 8191 and 4320 out of 7967 respectively in its category [2] - The fund manager, Li Zibo, has been in charge for 3 years and 250 days, with the fund's total asset size at 2.881 billion yuan, achieving a best return of 30.02% and a worst return of -2.1% during his tenure [2]